Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387903 | 0.85 | TSHR (0.45) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL4413450 | 0.83 | NPC1 (0.49) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL2290171 | 0.83 | ALDH1A1 (0.45) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL4380733 | 0.82 | EPHX2 (0.47) | MEN1KMT2ACYP2C9EPHX2LIPE | |
| SCHEMBL2298214 | 0.82 | CYP2C9 (0.49) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL4413446 | 0.81 | MEN1 (0.48) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL2294078 | 0.81 | EPHX2 (0.44) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL2296931 | 0.81 | MEN1 (0.54) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL13589003 | 0.81 | HTR2A (0.49) | MEN1KMT2AEPHX2LIPEEPHX1 | |
| SCHEMBL4386236 | 0.81 | HDAC3 (0.40) | MEN1KMT2ACYP2C9ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885CYP2C9 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.